Skip to main content


Selected Publications:

  1. Evans, J. P, C. Zeng, P. Qu, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of SARS-CoV-2 Deltacron and BA.3 Variants. New England Journal of Medicine. 386: 2340-2342.
  2. Qu, P, J. Faraone, J. P. Evans, Y.-M. Zheng, C. Carlin, J. S. Bednash, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine. 386: 2526-2528.
  3. Qu, P, J. Faraone, J. P. Evans, Y.-M. Zheng, L. Yu, Q. Ma, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, and S.-L. Liu. * 2022. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine. In Press. Sept 7, 2022.
  4. Evans, J. P, C. Zeng, P. Qu, J. Faraone, Y.-M. Zheng, C. Carlin, J. S. Bednash, T. Zhou, G. Lozanski, R. Mallampalli, L. J. Saif, E. M. Oltz, P. Mohler, K. Xu, R. J. Gumina, and S.-L. Liu. * 2022. Neutralization of SARS-CoV-2 Omicron Sub-lineages BA.1, BA.1.1 and BA.2 and BA. Cell Host & Microbe. S1931-3128(22)00220-7.
  5. Cui, Z, C. Zeng, F. Huang, F. Yuan, J. Yan, Y. Zhao, J. Huang, H. F. Staats, Jeffrey I. Everitt, G. D. Sempowski, H. Wang1, Y. Dong3*, S.-L. Liu*, and Q. Wang*. 2022. Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. Nature Chemical Biology. July 25, 2022. doi: 10.1038/s41589-022-01094-4.
  6. Tang, J., C. Zeng, T. M. Cox,C. Li, Y. M. Son, I. S. Cheon, Y. Wu, S. Behl, J. J. Taylor, R. Chakaraborty, A. J. Johnson, D. N Shiavo, J. P. Utz, J. S. Reisenauer, D. E. Midthun, J. J. Mullon, E. S. Edell, M. G. Alameh, L. Borish, M. H. Kaplan, D. Weissman, R. Kern, H. Hu, R.  Vassallo, S.-L. Liu*, and J. Sun*. 2022. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Science Immunology. July 19, 2022. doi: 10.1126/sciimmunol.add4853.
  7. Azar, J., J. P. Evans, M. Sikorski, K. Chakravarthy, S. McKenney, I. Carmody, C. Zeng, R. Teodorescu, N. J. Song, J. Hamon, D. Bucci, M. Velegraki, C. Bolyard, K. P. Weller, S. Reisinger, S. A. Bhat, K. J. Maddocks, R. J. Gumina, A. N. Vlasova, E. M. Oltz, L. J. Saif, D. Chung, J. A. Woyach, P. G. Shields, S.-L. Liu*, Z. Li*, M. P. Rubinstein*. 2022. Suppression of de novo antibody responses against SARS-CoV2 and the Omicron variant after mRNA vaccination and booster in patients with B cell malignancies undergoing active treatment, but maintenance of pre-existing antibody levels against endemic viruses. JCI Insight. In Revision.
  8. Abdelhamid, A. G, J. N. Faraone, J. P. Evans, S.-L. Liu, and A. E. Yousef. 2022. SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. Pathogens. July 27, 2022.
  9. Evans, J. P., C. Zeng, C. Carlin, G. Lozanski, L. J. Saif, E. M. Oltz, R. J. Gumina, and S.-L. Liu*. 2022. Neutralizing Antibody Responses Elicited by SARS-CoV-2 mRNA Vaccination Wane Over Time and are Boosted by Breakthrough Infection. Sci Transl Med. 14 (637): eabn8057.
  10. Zeng C, J.P., Evans, K. Chakravarthy, P. Qu, S. Reisinger, N.-J. Song N, M.P. Rubinstein M, P.G. Shields, Z. Li Z, and S.-L. Liu*. 2022. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. Dec 30: S1535-6108(21)00688-7.
  11. Zeng C, J. P., Evans JP, T, King, Y.-M. Zheng, E. M., Oltz, S. P. J, Whelan, L. J. Saif, M. E., Peeples ME, and S.-L. Liu*. 2021. SARS-CoV-2 Spreads through Cell-to-Cell Transmission. Proc. Natl. Acad. Sci. USA. 119(1): e2111400119.
  12. Zeng, C, J. P. Evans, J. N. Faraone, P. Qu, Y.-M. Zheng, L. J. Saif, E. M. Otlz, G. Lozanski, R. J. Gumina and S.-L. Liu*. 2021. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. mBio. 12(5): e0251021.
  13. Zeng, C, A. A. Waheed, T. Li, J. Yu, Y.-M. Zheng, J. Yount, H. Wen, E.O. Freed, and S.-L. Liu*. 2021. SERINC Proteins Potentiate Antiviral Type I IFN Induction and Proinflammatory Signaling Pathways. Science Signaling 14: eabc7611, Sept 14.
  14. Zeng, C, J. P. Evans, S. Reisinger, J. Woyach, C. Liscynesky, Z. E. Boghdadly, M. P. Rubinstein, K. Chakravarthy, L. Saif, E. M. Oltz, R. J. Gumina, *Peter G. Shields, Z. Li*, and S.-L. Liu*. 2021. Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccine in Cancer Patients. Cell & Bioscience. 11(1):197.
  15. Gyang, TC*, J. P. Evans, J. Miller, K. Alcorn, J. Peng, E. Bell, C. Zeng, R. J. Gumina, B. Segal, and S.-L. Liu*. 2021. Efficacy of SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis. Multiple Sclerosis Journal—Experimental, Translational and Clinical. 8(1): 20552173221087357.
  16. Lu, M, P. Dravid, Y. Zhang, S. Trivedi, A. Li, O. Harder, K.C. Mahesh, S. Chaiwatpongsakorn, A. Zani, A. Kenney, C. Zeng, C. Cai, C. Ye, X. Liang, M. Shimamura, S.-L. Liu, P. N Boyaka, J. Qiu, L. Martinez-Sobrido, J. Yount, M. Peeples, Kapoor, S. Niewiesk, and J. Li. 2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc. Natl. Acad. Sci. USA. Mar 23;118(12): e2026153118.
  17. Evans, J. P, and S.-L. Liu*. 2021. Role of host factors in SARS-CoV-2 Entry. J. Biol. Chem. 297(1):100847.
  18. Kim, E, Z. Attia, R. M. Woodfint, C.Zeng, S. Kim, H. E. Steiner, R. K. Shukla, N. P. M. Liyanage, J. Li, G. J. Renukaradhya, A. A. Satoskar, A. O. Amer, S.-L. Liu, E. Cormet-Boyaka, and P. N. Boyaka. 2021. Inhibition of elastase enhances the adjuvanticity of alum and promotes anti–SARS-CoV-2 systemic and mucosal immunity. Proc. Natl. Acad. Sci. USA. 118 (34) e2102435118.
  19. Lu M, Y. Zhang, P. Dravid, A. Li, C. Zeng, K C Mahesh, S. Trivedi, H. Sharma, S. Chaiwatpongsakorn, A. Zani, A. Kenney, C. Cai, C. Ye, X. Liang, J. Qiu, L. Martinez-Sobrido, J. S. Yount, P. N. Boyaka, S.-L. Liu, M. E. Peeples, A. Kapoor, J. Li J. 2021. A methyltransferase-defective VSV-based SARS-CoV-2 vaccine candidate provides complete protection against SARS-CoV-2 infection in hamsters. J. Virol. doi: 10.1128/JVI.00592-21
  20. Zeng, C, J. P. Evans, R. Pearson, P. Qu, Y.-M. Zheng, R. T. Robinson, L. Hall-Stoodley, J. Yount, S. Pannu, R. K. Mallampalli, L. Saif, E. Oltz, G. Lozanski, and S.-L. Liu*. 2020. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors. JCI Insight. 5(22): e143213.
  21. Wu, Y, W. Ho, Y. Huang, D.-Y. Jin, S. Li, S.-L. Liu, X. Liu, J, Qiu, Y. Sang, Q. Wang, K.-Y. Yuen, and Z.-M. Zheng. 2020. SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet 395 (10228): 949-950.
  22. Liu, S.-L.*, L. Saif, S. R. Weiss, and L. Su*. 2020. No Credible Evidence Supporting Claims of the Laboratory Engineering of SARS-CoV-2. Emerg. Microbes & Infect. 9(1):505-507. doi: 10.1080/22221751.2020.1733440.
  23. M. Chemudupati, A. Smith, R. Fillinger, A. Kenney, L. Zhang, A. Zani, S.-L. Liu, M. Z. Anderson, A. Sharma, and J. Yount. 2020. Butyrate Reprograms Expression of Specific Interferon- Stimulated Genes. J. Virol. 94 (16). E00326-20.
  24. Zeng, C, A. A. Waheed, T. Li, J. Yu, Y.-M. Zheng, J. Yount, H. Wen, E.O. Freed, and S.-L. Liu*. 2020. SERINC Proteins Potentiate Antiviral Type I IFN Induction and Proinflammatory Signaling Pathways. Proceedings. 2020, 50, 51; doi:10.3390.
  25. Liu, S.-L*. New Virus in China Requires International Control Effort. 2020. Nature 577(7791): 472.
  26. Liu, S.-L.*, and L. Saif. 2020. Emerging Viruses without Borders: The Wuhan Coronavirus. Viruses. 12(2). pii: E130. doi: 10.3390/v12020130.
  27. Li, A. Xue, Z. Attia, J. Yu, M. Lu, C. Shan, X. Liang, T. Z. Gao, P.-Y. Shi, M. E Peeples, P. N. Boyaka, S.-L. Liu, J. Li. 2020. Vesicular Stomatitis Virus and DNA Vaccines Expressing Zika Virus Nonstructural Protein 1 Induce Substantial but Not Sterilizing Protection against Zika Virus Infection. J. Virol. 94 (17): e00048-20.
  28. Li, M.#, A. A. Waheed#,J. Yu#, C. Zeng, H.-Y. Chen,Y.-M. Zheng, A. Feizpour, B. Reinhard, S. Gummuluru,S. Lin, E. O. Freed, and S.-L. Liu*. 2019. TIM-mediated Inhibition of HIV-1 Release Is Antagonized by Nef but Potentiated by SERINC Proteins. Proc. Natl. Acad. Sci. USA. 116 (12): 5705-5714. (#Co-first author)
  29. Yu, J, C. Liang, and S.-L. Liu*. 2019. CD4-dependent Modulation of HIV-1 Entry by LY6E. J. Virol. 93 (7): pii: e01866-18.
  30. Yu, J and S.-L. Liu*. 2019. Emerging Role of LY6E in Virus-Host Interactions. Viruses. 11 (11). piiE: 1020.
  31. Zani, A, L. Zhang, T. M. McMichael, A. Kenney, M. Chemudupati, J. J. Kwiek, S.-L. Liu, and J. S. Yount. 2019. IFITMs Inhibit Cell Fusion Mediated by Trophoblast Syncytins. J. Biol. Chem. Nov 17. pii: jbc.AC119.010611.
  32. Yu, J, V. Murthy, and S.-L. Liu*. 2019. Relating GPI-anchored Ly6/uPAR and CD59 Proteins to Viral Infection. Viruses. 11 (11). pii E:1060.
  33. Evans, J and S-L. Liu.* 2019. Multifaceted Roles of TIM-family Proteins in Virus-host Interactions. Trends Microbiol. pii: S0966-842X (19)30259-8.
  34. Beitari, S, Y. Wang, S.-L. Liu and C. Liang. 2019. HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion. Viruses, 11(4), 311.
  35. Lu S, Z Han, M.-C. Hung, J Xu, Y,Xu, P Zheng, Z.-M. Zheng, L. Zou, Z Li, L Zheng, Y Kang, Y Yang, L He, X.-C. Liao, H Yu, Z Yue, S.-L. Liu* and H Zheng. 2019. Racial Profiling Harms Science. Science 363(6433):1290-1292.
  36. Wang, T, Q. Du, Y. Niu, X. Zhang, M. He, Z. Wang, X. Wu, X. Yang, X. Zhao, S.-L. Liu, D. Tong, and Y. Huang. 2019. Cellular p32 Is a Critical Regulator of the Porcine Circovirus Type 2 Nuclear Egress. J. Virol. 93(23). pii: e00979-19.
  37. Kodigepalli, K.M, M. Li, S. Bonifati, S.-L. Liu, and L. Wu. 2018. SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle. Nov 26. doi: 10.1080/15384101.2018.1550955.
  38. Yu, J, and S.-L. Liu*. 2018. The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage. Viruses 10 (8). Pii: E413.
  39. Li, A., J. Yu, M. Lu, Y. Ma, Z. Attia, C. Shan, J. He, X. Liang, M. Xue, R. Jennings, P.-Y. Shi, M. Peeples, S.-L. Liu, P. Boyaka, J. Li. 2018. A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat. Commun. 9 (1): 3067.
  40. Yu, J., C. Liang and S.-L. Liu*. 2017. Interferon-inducible LY6E Protein Promotes HIV Infection. J. Biol. Chem. 292(11):4674-4685.
  41. Wang, Y., Q. Pan, Z. Wang, J. Yu, S.-L. Liu and C. Liang. 2017. The V3-loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. J. Virol. 91(7). pii: e02441-16.
  42. Miller, A.D., M. de Las Heras, J. Yu, F. Zhang, S.-L. Liu, A. E. Vaughan, T. L. Vaughan, R. Rosadio, S. Rocca, G. Palmieri, J. J.Goedert, J. Fujimoto, I. I. Wistuba. 2017. Evidence against a role for Jaagsiekte sheep retrovirus in human lung cancer. Retrovirology. 14(1):3.
  43. Markosyan, R.M.#, C. Miao#, Y.-M. Zheng, G.B. Melikian, S.-L. Liu* and F.S. Cohen*. 2016. Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is not a Trigger. PLoS Pathogens. 12(1): e1005373. (# Co-first author)
  44. Miao, C, M. Li, Y.-M. Zheng, F. S. Cohen and S.-L. Liu*. 2015. Cell-cell Contact Promotes Ebola Virus GP-mediated Infection. Virology. 488:202-215.
  45. Yu, J, M. Li, J. Wilkins, S. Ding, T. H. Swartz, A. M. Esposito, Y.-M. Zheng, E. O. Freed, C. Liang, B. K. Chen, and S.-L. Liu*. 2015. IFITM Proteins Antagonize HIV-1 Envelope to Restrict Cell-to-cell Infection. Cell Reports 13: 145-156.
  46. Li, K, R. Jia, M. Li, Y.-M. Zheng, C. Miao, Y. Yao, H. Ji, Y. Geng, W. Qiao, Lorraine M. Albritton, Chen Liang, and S.-L. Liu*. 2015. A Sorting Signal Intrinsically Suppresses IFITM1 Restriction of Viral Entry. J. Biol. Chem. 290 (7): 4248-4259.
  47. Li, M, S. Ablan, C. Miao, Y.-M. Zheng, M. S. Fuller, P. D. Rennert, W. Maury, M. Johnson, E. O. Freed, and S.-L. Liu*. 2014 TIM Family Proteins Inhibit HIV-1 Release. Proc Natl Acad Sci USA. 111(35): E3699-707.
  48. Ding, S, Q. Pan, S.-L. Liu*, and C. Liang*. 2014. HIV-1 mutates to escape IFITM1 restriction. Virology 454-455: 11-24
  49. Li K#, R. M. Markosyan#, Y.-M. Zheng#, O. Golfetto, B. Bungart, M. Li, S. Ding, Y. He, C. Liang, J. C. Lee, E. Gratton, F. S. Cohen, and S.-L. Liu*. 2013. IFITM Proteins Restrict Viral Membrane Hemifusion. PLoS Pathogens. 9 (1): e1003124. (# equal contribution)
  50. Côté M.#, Y.-M. Zheng#, and S.-L. Liu*. 2012. Membrane fusion and cell entry of XMRV is pH-independent and modulated by the envelope glycoprotein’s cytoplasmic tail. PLoS ONE. 7(3):e33734. (#equal contribution)
  51. Côté M#, Y.-M. Zheng#, Kun Li, S-H Xiang, Lorraine M. Albritton and S.-L. Liu*. 2012. Critical Role of a Leucine-Valine Change in the Distinct Low pH Requirements for Membrane Fusion between Two Related Retrovirus Envelopes. J. Bio. Chem. 287(10):7640-51. (#equal contribution)
  52. Côté M., Y.-M. Zheng and S.-L. Liu*. 2011. Single Residues in the Surface Subunits of Oncogenic Sheep Retrovirus Envelopes Distinguish Their Receptor-mediated Triggering for Fusion at Low pH and Infection. Virology 421(2): 173-183.
  53. Lu J, Q. Pan Q, L. Rong, S.-L. Liu, and Liang C. 2011. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85: 2126-2137.
  54. Côté M., Y.-M. Zheng and S.-L. Liu*. 2009.  Receptor Binding and Low pH Coactivate Oncogenic Retrovirus Envelope-mediated Fusion. J. Virol. 83: 1144-11455.
  55. Côté M., T. Kucharski, Y.-M. Zheng and S.-L. Liu*. 2008. Enzootic Nasal Tumor Virus Requires a Very Acidic pH for Fusion Activation and Infection. J. Virol. 82: 9023-9034.
  56. Côté M., Y.-M. Zheng, L. M. Albritton, and S.-L. Liu*. 2008. The Fusogenicity of Jaagsiekte Sheep Retrovirus Envelope Glycoprotein is Dependent on Low pH and Is Enhanced by the Cytoplasmic Tail Truncations.  J. Virol. 82: 2543-2554.
  57. Bertrand P., M. Côté, Y.-M. Zheng, L. M. Albritton, and S.-L. Liu*. 2008. Jaagsiekte Sheep Retrovirus Utilizes a pH-dependent Endocytosis Pathway for Entry. J. Virol. 82:2555-2559.
  58. Liu S.-L.* and A. D. Miller. 2007. Oncogenic Transformation by the Jaagsiekte Sheep Retrovirus Envelope Protein. Oncogene. 26:789-01.
  59. M. Cote, A. D. Miller, and S.-L. Liu*. 2007. Human RON Receptor Tyrosine Kinase Induces Complete Epithelial-To-Mesenchymal Transition but Impairs Cell Proliferation. Biochem. Biophys. Res. Commun. 360:219-25.
  60. Liu S.-L. and A. D. Miller. 2005. Transformation of Madin-Darby Canine kidney (MDCK) Epithelial Cells by Sheep Retrovirus Env Proteins. J. Virol. 79: 927-933.
  61. Liu S.-L., C. L. Halbert, and A. D. Miller. 2004. The Env Glycoprotein of Jaagsiekte Sheep Retrovirus Efficiently Pseudotypes the HIV-1 Lentiviral Vectors. J. Virol. 78: 2642-2647.
  62. Liu S.–L., M. I. Lerman, and A. D. Miller. 2003. Putative PI3K Binding Motifs in Ovine Betaretrovirus Env Proteins Are Not Essential for Rodent Fibroblast Transformation and PI3K/Akt Activation. J. Virol. 77: 7924-7935.
  63. Liu S.-L., F. M. Duh, M. I. Lerman, and A. D. Miller. 2003. Role of Virus Receptor Hyal2 in Oncogenic Transformation of Rodent Fibroblasts by Sheep Betaretrovirus Env Proteins. J. Virol., 77: 2850-2858.
  64. Danilkovitch-Miagkova A, F. M. Duh, I. Ikuzmin, D. Angeloni, S.-L. Liu, A. D. Miller,and M. I. LermanMI. 2003.  Candidate Tumor Suppressor HYAL2 Is a Negative Regulator of RON Receptor Tyrosine Kinase and Mediates Transformation of Epithelial Cells by Jaagsiekte Sheep Retrovirus. Proc. Natl. Acad. Sci.  USA. 100: 4580-4585.
  65. Liu S.-L., J. M. Mittler, D. C. Nickle, T. Mulvania, D. Shriner, A.G. Rodrigo, B. Kosloff, X. He, L. Corey, and J. I. Mullins. 2002. Selection for Human Immunodeficiency Virus Type 1 Recombinants in A Patient with Rapid Progression to AIDS. J. Virol., 76: 10674-10684.
  66. Liu, S.-L., T. Schacker, L. Musey, D. Shriner, M. J. McElrath, L. Corey, and J. I. Mullins. 1997. Divergent Patterns of Progression to AIDS After Infection from the Same Source: HIV-1 Evolution and Antiviral Responses. J. Virol. 71: 4284- 4295.
  67. Liu, S.-L., A. G. Rodrigo, R. Shankarappa, G. H. Learn, L. Hsu, O. Davidov, L.-P. Zhao, and J. I. Mullins. 1996. HIV Quasispecies and Resampling. Science. 273: 415-416.